As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate.
As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing a similar Sovaldi situation, as well as the other new, high cost, American biotech products that are beginning to appear there.
As a quick review, Health Canada is a single payer healthcare system that has a governmental obligation to provide healthcare to all Canadians. Although predicated on a complicated system of federal and provincial medical cooperation, the approach has evolved since 1946 into a fairly comprehensive, public form of single payer healthcare coverage.
However, recently the Canadian healthcare system has been disturbed by the arrival of several American biotech drugs - the same breakthrough drugs that are creating so much controversy in the U.S. How has this situation played out in Canada versus the invective that’s been experienced in the U.S.?
To put it succinctly, differently… Very differently.
For the full version of this article, click here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.